SG10202000463YA - 2-acylaminothiazole derivative or salt thereof - Google Patents

2-acylaminothiazole derivative or salt thereof

Info

Publication number
SG10202000463YA
SG10202000463YA SG10202000463YA SG10202000463YA SG10202000463YA SG 10202000463Y A SG10202000463Y A SG 10202000463YA SG 10202000463Y A SG10202000463Y A SG 10202000463YA SG 10202000463Y A SG10202000463Y A SG 10202000463YA SG 10202000463Y A SG10202000463Y A SG 10202000463YA
Authority
SG
Singapore
Prior art keywords
bladder
dysfunction
receptor
preventing
muscarinic
Prior art date
Application number
SG10202000463YA
Inventor
Taisuke Takahashi
Takanori Koike
Kenji Negoro
Hiroaki Tanaka
Jun Maeda
Kazuhiro Yokoyama
Hajime Takamatsu
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of SG10202000463YA publication Critical patent/SG10202000463YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

[Abstract] [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M 3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, for example voiding dysfunction such as underactive bladder. [Selected Figure] Nil
SG10202000463YA 2014-06-06 2015-06-05 2-acylaminothiazole derivative or salt thereof SG10202000463YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014118046 2014-06-06

Publications (1)

Publication Number Publication Date
SG10202000463YA true SG10202000463YA (en) 2020-02-27

Family

ID=54766887

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202000463YA SG10202000463YA (en) 2014-06-06 2015-06-05 2-acylaminothiazole derivative or salt thereof
SG11201610201UA SG11201610201UA (en) 2014-06-06 2015-06-05 2-acylaminothiazole derivative or salt thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201610201UA SG11201610201UA (en) 2014-06-06 2015-06-05 2-acylaminothiazole derivative or salt thereof

Country Status (34)

Country Link
US (2) USRE49111E1 (en)
EP (1) EP3153511B1 (en)
JP (1) JP6319436B2 (en)
KR (1) KR102482844B1 (en)
CN (2) CN110845490B (en)
AR (1) AR100748A1 (en)
AU (1) AU2015269449B2 (en)
BR (1) BR112016028270B1 (en)
CA (1) CA2950564C (en)
CO (1) CO2017000044A2 (en)
CY (1) CY1122290T1 (en)
DK (1) DK3153511T3 (en)
EA (1) EA031866B1 (en)
ES (1) ES2732066T3 (en)
HR (1) HRP20190943T1 (en)
HU (1) HUE043496T2 (en)
IL (1) IL249356B (en)
LT (1) LT3153511T (en)
MA (1) MA39950B1 (en)
ME (1) ME03438B (en)
MX (1) MX370140B (en)
MY (1) MY197712A (en)
NZ (1) NZ727142A (en)
PH (1) PH12016502405A1 (en)
PL (1) PL3153511T3 (en)
PT (1) PT3153511T (en)
RS (1) RS58809B1 (en)
SA (1) SA516380427B1 (en)
SG (2) SG10202000463YA (en)
SI (1) SI3153511T1 (en)
TR (1) TR201908676T4 (en)
TW (2) TWI689507B (en)
UA (1) UA122208C2 (en)
WO (1) WO2015186821A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4886041B2 (en) 2006-12-20 2012-02-29 ジーブイビービー ホールディングス エス.エイ.アール.エル. Embedded audio routing selector
EP3196200B1 (en) 2014-08-26 2019-05-08 Astellas Pharma Inc. 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases
CA3044366A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
WO2019189766A1 (en) * 2018-03-30 2019-10-03 持田製薬株式会社 Novel biaryl amide derivative
CN111718293A (en) * 2019-03-18 2020-09-29 持田制药株式会社 Process for producing bisarylamide derivative
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (en) * 1999-12-07 2005-08-15 Тераванс, Інк. Urea derivatives, a pharmaceutical composition and use of derivative in the preparation of medicament for the treatment of disease being mediated by muscarine receptor
JP2001278872A (en) 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd New aminothiazole derivative
HUP0302010A2 (en) * 2000-05-25 2003-09-29 F.Hoffmann-La Roche Ag. Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists, production of the compounds and pharmaceutical compositions containing them
JPWO2003037862A1 (en) * 2001-10-30 2005-02-17 日本新薬株式会社 Amide derivatives and pharmaceuticals
PT1466912E (en) * 2002-01-18 2013-06-28 Astellas Pharma Inc 2-acylaminothiazole derivative or salt thereof
TWI242478B (en) 2002-08-01 2005-11-01 Masami Nakamoto Metal nanoparticle and process for producing the same
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
KR100907317B1 (en) 2003-07-17 2009-07-13 아스텔라스세이야쿠 가부시키가이샤 2-acylaminothiazole derivative or salt thereof
JP4774995B2 (en) * 2005-01-12 2011-09-21 アステラス製薬株式会社 Pharmaceutical composition comprising an acylaminothiazole derivative as an active ingredient
JP4665769B2 (en) 2005-01-12 2011-04-06 アステラス製薬株式会社 Method for producing acylaminothiazole derivative
CN101490003A (en) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder
SI2206707T1 (en) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
EP2598483B1 (en) 2010-07-29 2020-07-29 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
TWI647227B (en) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-guanamine thiazole derivative or a salt thereof

Also Published As

Publication number Publication date
AU2015269449A1 (en) 2016-12-22
MY197712A (en) 2023-07-09
US20170197955A1 (en) 2017-07-13
USRE49111E1 (en) 2022-06-21
MA39950A (en) 2017-04-12
TWI689507B (en) 2020-04-01
ES2732066T3 (en) 2019-11-20
IL249356B (en) 2019-11-28
CN110845490A (en) 2020-02-28
JP6319436B2 (en) 2018-05-09
PH12016502405B1 (en) 2017-02-20
PH12016502405A1 (en) 2017-02-20
WO2015186821A1 (en) 2015-12-10
NZ727142A (en) 2022-10-28
KR20170013987A (en) 2017-02-07
EP3153511A4 (en) 2017-12-06
SG11201610201UA (en) 2017-01-27
MX2016016134A (en) 2017-03-08
ME03438B (en) 2020-01-20
MA39950B1 (en) 2019-08-30
KR102482844B1 (en) 2022-12-30
BR112016028270A2 (en) 2022-07-19
CY1122290T1 (en) 2021-01-27
IL249356A0 (en) 2017-02-28
JPWO2015186821A1 (en) 2017-04-20
TW201613914A (en) 2016-04-16
CA2950564A1 (en) 2015-12-10
EA201692469A1 (en) 2017-05-31
LT3153511T (en) 2019-07-10
TW202026294A (en) 2020-07-16
CN110845490B (en) 2023-03-28
EP3153511A1 (en) 2017-04-12
US9951060B2 (en) 2018-04-24
MX370140B (en) 2019-12-03
SA516380427B1 (en) 2019-11-28
HUE043496T2 (en) 2019-08-28
UA122208C2 (en) 2020-10-12
TWI745877B (en) 2021-11-11
RS58809B1 (en) 2019-07-31
TR201908676T4 (en) 2019-07-22
AU2015269449B2 (en) 2019-03-14
EP3153511B1 (en) 2019-05-15
CN106414438B (en) 2019-12-31
DK3153511T3 (en) 2019-06-24
CO2017000044A2 (en) 2017-03-31
HRP20190943T1 (en) 2019-09-20
CA2950564C (en) 2023-03-07
PT3153511T (en) 2019-06-28
SI3153511T1 (en) 2019-08-30
AR100748A1 (en) 2016-10-26
BR112016028270B1 (en) 2023-05-02
BR112016028270A8 (en) 2023-01-17
PL3153511T3 (en) 2019-09-30
EA031866B1 (en) 2019-03-29
CN106414438A (en) 2017-02-15

Similar Documents

Publication Publication Date Title
SG10202000463YA (en) 2-acylaminothiazole derivative or salt thereof
SA515360956B1 (en) 2-Acylaminothiazole derivative or salt thereof
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2016001400A (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
MX2020007023A (en) Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions.
ECSP13013038A (en) ACETIL-COA CARBOXILASA REPLACED INHIBITORS
MX2011013437A (en) Histamine h3 inverse agonists and antagonists and methods of use thereof.
BR112017016817A2 (en) heterocyclic derivatives formulated as fgfr4 inhibitors
EA201300436A1 (en) JOINT CRYSTALS AND SALTS OF CCR3 INHIBITORS
MX2016014946A (en) Carboxamide derivatives.
MX2016014939A (en) Carboxamide derivatives.
PH12015502341A1 (en) Heterocyclic acetic acid amide compound
CY1119483T1 (en) THERAPEUTIC PARTY FOR ANXIETY DISORDERS
WO2011031816A3 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
MX2017002500A (en) 2-aminothiazole derivative or salt thereof.
TH168973B (en) 2-azyl aminothiazole derivatives Or its salt
TH178650B (en) 2-azyl aminothiazole derivatives (2-ACYLAMINOTHIAZOLE) or their salt.
TH168973A (en) 2-azyl aminothiazole derivatives Or its salt
PH12016502247A1 (en) Carboxamide derivatives
TH178650A (en) 2-azyl aminothiazole derivatives (2-ACYLAMINOTHIAZOLE) or their salt.